Ocular Therapeutix (OCUL) Total Liabilities (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Total Liabilities of $151.3 million for Q2 2026, up 4.03% year-over-year from $145.4 million in Q2 2025, and little changed on a QoQ basis from $151.0 million in Q1 2026.
Ocular Therapeutix (OCUL) Total Liabilities (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Total Liabilities for 14 years, with the latest figure at $151.3 million in Q2 2026.
- Total Liabilities for Q2 2026 came in at $151.3 million, up 4.03% year-over-year; the trailing twelve-month figure through Jun 2026 was $151.3 million (up 4.03% YoY), and the FY2025 annual result was $153.7 million, up 7.82% from the prior year.
- Total Liabilities was little changed at $151.3 million in Q2 2026, from $151.0 million in the prior quarter.
- Over five years, Total Liabilities peaked at $160.9 million in Q4 2023 and troughed at $107.3 million in Q2 2022.
- A 5-year average of $135.6 million and a median of $139.7 million in 2024 frame the typical range for Total Liabilities.
- The widest annual swing landed in 2022, when Total Liabilities slumped 32.45%; it then soared 41.28% in 2023.
- A 5-year view of Total Liabilities shows it stood at $113.9 million in 2022, then soared by 41.28% to $160.9 million in 2023, then declined by 11.4% to $142.6 million in 2024, then advanced by 7.82% to $153.7 million in 2025, then slipped by 1.61% to $151.3 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $151.3 million in Q2 2026, $151.0 million in Q1 2026, and $153.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 151.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 151.28 Mn |
| Mar 31, 2026 | 150.96 Mn |
| Dec 31, 2025 | 153.75 Mn |
| Sep 30, 2025 | 152.65 Mn |
| Jun 30, 2025 | 145.42 Mn |
| Mar 31, 2025 | 139.99 Mn |
| Dec 31, 2024 | 142.59 Mn |
| Sep 30, 2024 | 138.35 Mn |
| Jun 30, 2024 | 139.40 Mn |
| Mar 31, 2024 | 130.96 Mn |
| Dec 31, 2023 | 160.93 Mn |
| Sep 30, 2023 | 154.53 Mn |
| Jun 30, 2023 | 119.47 Mn |
| Mar 31, 2023 | 118.86 Mn |
| Dec 31, 2022 | 113.91 Mn |
| Sep 30, 2022 | 112.35 Mn |
| Jun 30, 2022 | 107.27 Mn |
| Mar 31, 2022 | 107.83 Mn |
| Dec 31, 2021 | 116.89 Mn |
| Sep 30, 2021 | 130.40 Mn |